Biocept reports profitability for the first half on back of increased COVID-19 testing
Biocept Inc (NASDAQ:BIOC) reported positive net income for the first half of 2021 as revenues rose due to the increased use of the firm’s COVID-19 RT-PCR tests, notably in the first quarter.
In the six months to June 30 this year, the diagnostics group posted a net income of $772,000 compared to a net loss of $14.8 million in the same period of 2020 on revenue of $29.8 million, a large increase from the revenue figure of $2.4 million seen in the first half of 2020.
READ: Biocept appoints David Karlander as senior vice president of Commercial Operations
Meanwhile, in the second quarter (to end-June), revenue was $12 million, up from $917,000 in 2Q, 2020, while the net loss was $1.8 million, which was still an improvement from the loss of $6.4 million recorded in the second quarter of 2020.
“Revenues of $12.0 million for the quarter reflect the anticipated sequential quarter decline in COVID-19 testing as more Americans became vaccinated,” said Michael Nall, Biocept’s CEO in a statement.
“That said, COVID-19 testing volume in the current quarter is presently running at a higher rate than second-quarter levels largely due to the Delta variant with more than 50,000 samples received in the past month as we near the 500,000 sample milestone. We are prepared for increases in COVID-19 testing volume in the coming weeks as we begin receiving samples from California community college students returning to in-person classes.”
In the second quarter, Biocept signed an agreement to make its coronavirus testing available to the more than 2.1 million students, as well as faculty and staff of the California community college.
On its CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system, the firm said volume of the tests had “grown each consecutive quarter” since the beta launch in early 2020.
“We have now received orders from more than 30 leading U.S. academic institutions with the majority becoming repeat customers. Importantly, we have seen CNSide positively impact the life expectancy and the quality of life of patients who otherwise might be referred to hospice care,” said Nall.
The company boss added he was “pleased” with Medicare’s decision to provide coverage and high-value payment for the group’s Target Selector breast cancer assay that detects the HER2 biomarker.
“Testing for the HER2 biomarker is among the most important sources of information when making treatment decisions for patients diagnosed with breast cancer and is among our most frequently ordered assay profiles” he noted.
In other developments in the quarter, Samuel Riccitelli was named chairman, while the company’s board was expanded to nine with the appointments of Linda Rubinstein and Antonino Morales as directors.
In addition, Biocept common stock was added to the Russell Microcap Index, a broadly used performance benchmark for smaller growth stocks in the USA.
As of June 30 this year, Biocept had cash and cash equivalents of $19.5 million, compared with $14.4 million at the end of 2020.
During the three and six months ended June 30, 2021, the company raised net cash proceeds of $3.9 million through the sale of common stock under its at-the-market (ATM) facility.
Contact the author at [email protected]
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/957895/biocept-reports-profitability-for-the-first-half-on-back-of-increased-covid-19-testing-957895.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
